LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Turner, Martin; Singhrao, Simarjit Kaur; Dennison, Sarah Rachel; Morton, Leslie Hugh Glyn; Crean, Stjohn (2015)
Publisher: Austin Publishing group
Languages: English
Types: Article
Subjects:
In 2002, botulinum toxin type A (BoNT/A) was approved by the US Food and Drug Administration (FDA) for cosmetic use. However, there may be procedural differences between the ways in which a clinician handles, applies and stores the product compared to the suggested guidelines of the manufacturer for handling and storage. To this end vials (N = 12) of BoNT/A were tested for the incidence of microbial contamination followed by challenging the product with a selection of microorganisms by culture methods and by using a calcein release assay to contaminate multi-dose vials at the single concentration used for facial aesthetics. A culture, droplet method was used to count microorganisms challenged with the therapeutic product and to compare viability levels in appropriate controls as well as measuring their lytic properties via an existing cell-free system involving calcein release. Counts of test organisms within the droplets, with the product and the controls without the product were undertaken using Image J software. The result from the incidence of in-vial contamination was inconclusive. Bacterial levels between controls and product challenged groups demonstrated no differences in the growth of viable microorganisms following immediate contact (p = ≥ 0.05). The cell-free calcein release assay demonstrated differences at all time points for low levels of lysis in each case with bacterial lipid extract and were statistically significant (p = 0.011). Although these data appear to correlate with the minimum inhibitory concentration, the additives and vial integrity are also likely to contribute to the maintenance of BoNT/A sterility.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Hill KK, Smith TJ. Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr. Top Microbiol. Immunol 2013; 364: 1-20.
    • 2. Poulain B, Popoff MR, Molgó J. 'How do the Botulinum Neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action'. The Botulinum J 2008; 1: 14-87.
    • 3. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum - A exotoxin. J Dermatol Surg Oncol 1992; 18: 17-21.
    • 4. Simpson LL. Identification of the characteristics that underlie botulinum toxin potency: Implications for designing novel drugs. Biochimie 2000; 82: 943- 953.
    • 5. Brin MF, Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997; 6: S146-168.
    • 6. Binz T, Rummel A. Cell entry strategy of clostridial neurotoxins. J. Neurochem 2009; 109: 1584-1595.
    • 7. Clark RP, Berris CE. Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis. Plast Reconstr Surg 1989; 84: 353-355.
    • 8. Winter L, Spiegel J. Botulinum toxin type-A in the treatment of glabellar lines. Clin Cosmet Investig Dermatol 2009; 22: 1-4.
    • 9. Kim J. Contralateral botulinum toxin injection to improve facial asymmetry after acute facial paralysis. Otol Neurotol 2013; 34: 319-324.
    • 10. Mustafa G, Anderson EM, Bokrand-Donatelli Y, Neubert JK, Caudle RM. Antinociceptive effect of a conjugate of substance P and light chain of botulinum neurotoxin type A. Pain 2013; 154: 2547-2553.
    • 11. Gazerani P, Au S, Dong X, Kumar U, Arendt-Nielsen L, et al. Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis. Pain 2010; 151: 606-616.
    • 12. Dennison SR, Phoenix DA, Snape TJ. Synthetic oligoureas of metaphenylenediamine mimic host defence peptides in their antimicrobial behavior. Bioorg Med Chem Lett 2013; 23: 2518-2521.
    • 13. Ratledge C, Wilkinson SG. (eds) Microbial lipids 1988; l 1. Academic Press, London.
    • 18. Miles AA, Misra SS. The estimation of the bactericidal power of the blood. J. Hyg 1938; 38: 732-749.
    • 14. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Med Sci 1959; 37: 911-917.
    • 19. Menon J, Murray A. Microbial growth in vials of Botulinum toxin following use in clinic. Eye (Lond) 2007; 21: 995-997.
    • 15. Rose HG, Oklander M. Improved Procedure for the Extraction of Lipids from Human Erythrocytes. J Lipid Res 1965; 6: 428-431.
    • 16. Hexsel DM, De Almeida AT, Rutowitsch M, De Castro IA, Silveira VL, et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg 2003; 29: 523-529.
    • 17. Parsa AA, Lye KD, Parsa FD. Reconstituted botulinum type A neurotoxin: clinical efficacy after long-term freezing before use. Aesthetic Plast. Surg 2007; 31: 188-191.
    • 20. Alam M, Dover JS, Arndt KA. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial. Arch Dermatol 2002: 138: 510-514.
    • 21. Pickett A, Perrow K. Formulation composition of botulinum toxins in clinical use. J Drugs Dermatol 2010; 9: 1085-1091.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article